Part 1 - Case Presentation & Debate Setup

D. Ross Camidge, MD, PhD, and Erin Schenk, MD, PhD, medical oncologists at the University of Colorado Cancer Center, discuss the case of a 67-year-old woman with advanced stage IV ALK+ non-small cell lung cancer (NSCLC). In the context of this case, Dr Camidge poses a question to Dr Schenk about the utility of tumor markers vs. PET/CT in tracking disease progression and treatment efficacy.

Visit this link to continue to Part 2 - Case Discussion & Debate.

Disclosures:

Erin Schenk, MD, PhD
Consulting Fees: Guidepoint, Physicians’ Education Resource

D. Ross Camidge, MD, PhD
Consulting Fees: Amgen, Anchiarno, Apollomics, AstraZeneca, Bio-Thera, BMS, Daiichi-Sankyo, Eisai, Elevation, Eli Lilly, EMD Serono, GSK, Helssin, Janssen, Nuvalent, Onkure, Mersana, Pfizer, Qilu, Roche, Sanofi, Seattle Genetics, Takeda
Contracted Research: AbbVie, AstraZeneca, BMS, GSK, Hansoh, Inhibrx, Inivata, Karyopharm, Lycera, Medimmune, Merck, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Symphogen, Takeda, Tolero